Exploring decisional needs of adults considering first line treatment for advanced EGFR+ lung cancer: An interpretive descriptive study
Cancer Treatment and Research Communications · 2026
DOI: 10.1016/j.ctarc.2026.101321 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Rena Seeger und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Ottawa, Canada. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: With expanding treatment options for EGFRs+ metastatic non-small cell lung cancer (mNSCLC), shared decision-making is critical in aligning treatment plans with patient values. Oral targeted therapies offer convenience and independence and emerging therapies combining targeted therapies with various IV therapies show improved efficacy but with increased side effects and impacts on quality of life. This study explores the decisional needs of adults with EGFR+ mNSCLC considering first-line treatments. METHODS: We conducted an interpretive descriptive qualitative study guided by the Ottawa Decision Support Framework. INCLUSION CRITERIA: adults mEGFR+ NSCLC with current or prior Osimertinib therapy. Interviews were conducted using a standardized interview guide. Interview transcripts were analyzed using inductive thematic analysis and mapped onto the Framework. RESULTS: The 16 participants were aged 48-83 years (median 62); 11 female; 13 currently taking Osimertinib; and time since diagnosis was 2 to 78 months. Decisional needs include inadequate discussion on alternatives; decisions under pressure; feeling overloaded with written information; desire for value-aligned treatment; deferring to trusting relationships; strong emotions interfering with decision-making; desire for structured decisional supports. Participants valued Osimertinib's convenient oral delivery, minimal side effects, and ability to maintain independence. When asked about newer combined treatments, participants wanted more details so they could weigh the options to determine the best fit for their personal circumstances. CONCLUSION: Our findings emphasize the need for oncologists to recognize patients' decisional needs in treatment discussions and consider ways to support them to ensure treatment choices align with patients' informed values.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Ottawa, Canada.
- Faculty of Health Sciences, University of Ottawa, Canada; Ottawa Hospital Research Institute, Canada.
- Advocate living with Lung Cancer, Director: Lung Cancer Canada, Canada.
- Faculty of Medicine, University of Ottawa, Canada; Ottawa Hospital Research Institute, Canada. Electronic address: pwheatleyprice@toh.ca.
Zitieren
APA
Seeger, R., Stacey, D., Bossio, E., & Wheatley-Price, P. (2026). Exploring decisional needs of adults considering first line treatment for advanced EGFR+ lung cancer: An interpretive descriptive study. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2026.101321
Vancouver
Seeger R, Stacey D, Bossio E, Wheatley-Price P. Exploring decisional needs of adults considering first line treatment for advanced EGFR+ lung cancer: An interpretive descriptive study. Cancer Treatment and Research Communications. 2026. doi:10.1016/j.ctarc.2026.101321
BibTeX
@article{Seeger2026,
author = {Seeger, Rena and Stacey, Dawn and Bossio, Emi and Wheatley-Price, Paul},
title = {Exploring decisional needs of adults considering first line treatment for advanced EGFR+ lung cancer: An interpretive descriptive study},
journal = {Cancer Treatment and Research Communications},
year = {2026},
doi = {10.1016/j.ctarc.2026.101321}
}
EUVIMED